Type I interferons in anticancer immunity

Laurence Zitvogel; Lorenzo Galluzzi; Oliver Kepp; Mark J Smyth; Guido Kroemer

doi:10.1038/nri3845

Type I interferons in anticancer immunity

Nat Rev Immunol. 2015 Jul;15(7):405-14. doi: 10.1038/nri3845. Epub 2015 Jun 1.

Authors

Laurence Zitvogel¹, Lorenzo Galluzzi², Oliver Kepp³, Mark J Smyth⁴, Guido Kroemer⁵

Affiliations

¹ 1] [2] INSERM, U1015, F-94800 Villejuif, France. [3] Université Paris Sud/Paris XI, Faculté de Médecine, F-94270 Le Kremlin Bicêtre, France. [4] Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, F-94800 Villejuif, France. [5].
² 1] [2] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [3] INSERM, U1138, F-75006 Paris, France. [4] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [5] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [6].
³ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France.
⁴ 1] Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston QLD 4006, Australia. [2] School of Medicine, University of Queensland, Herston QLD 4006, Australia.
⁵ 1] Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, F-75006 Paris, France. [2] INSERM, U1138, F-75006 Paris, France. [3] Université Paris Descartes/Paris V, Sorbonne Paris Cité, F-75006 Paris, France. [4] Université Pierre et Marie Curie/Paris VI, F-75006 Paris, France. [5] Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, F-94800 Villejuif, France. [6] Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, F-75015 Paris, France.

PMID: 26027717
DOI: 10.1038/nri3845

Abstract

Type I interferons (IFNs) are known for their key role in antiviral immune responses. In this Review, we discuss accumulating evidence indicating that type I IFNs produced by malignant cells or tumour-infiltrating dendritic cells also control the autocrine or paracrine circuits that underlie cancer immunosurveillance. Many conventional chemotherapeutics, targeted anticancer agents, immunological adjuvants and oncolytic viruses are only fully efficient in the presence of intact type I IFN signalling. Moreover, the intratumoural expression levels of type I IFNs or of IFN-stimulated genes correlate with favourable disease outcome in several cohorts of patients with cancer. Finally, new anticancer immunotherapies are being developed that are based on recombinant type I IFNs, type I IFN-encoding vectors and type I IFN-expressing cells.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Animals
Humans
Immunotherapy / methods*
Interferon Type I / immunology*
Interferon Type I / therapeutic use
Neoplasms / immunology*

Substances

Interferon Type I